Olive S. Eckstein

Hematology | Oncology
6701 Fannin St
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis.

Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis.

Journal: Pediatric blood & cancer
Published: April 28, 2026

Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.

Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.

Journal: Immunotherapy
Published: June 18, 2025

Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

Journal: Blood advances
Published: April 22, 2025

Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

Journal: Blood advances
Published: April 22, 2025

BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH.

BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH.

Journal: Blood
Published: August 22, 2024

Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study.

Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study.

Journal: Blood advances
Published: July 23, 2024

Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.

Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 03, 2024

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.

Journal: Cancer
Published: January 16, 2024

Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.

Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.

Journal: Blood advances
Published: November 27, 2023

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.

Journal: British journal of haematology
Published: November 17, 2023

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.

Journal: British journal of haematology
Published: November 17, 2023
Showing 1-12 of 37

Last Updated: 09/26/2026